Iovance gets conditional Health Canada approval for Amtagvi

[Cancer Outbreak]
wildpixel/iStock via Getty Images

Iovance Biotherapeutics (NASDAQ:IOVA [https://seekingalpha.com/symbol/IOVA]) shares rose post market after it received Health Canada approval with conditions for its T-cell immunotherapy, Amtagvi (lifileucel), as a treatment of advanced melanoma.

The biotech company said that Amtagvi is the first T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy.

“We expect to authorize our first Canadian treatment center within the next few months, and we continue to advance our ex-U.S. strategy for Amtagvi in additional markets,” Frederick Vogt, interim CEO of Iovance, said in a statement [https://seekingalpha.com/pr/20204235-iovance-s-amtagvi-lifileucel-receives-health-canada-approval-for-advanced-melanoma].

Shares of the company are up about 7% after the bell.

The market authorization, under the NOC/c guidance, is conditional, pending the results of trials to confirm Amtagvi's clinical benefit, the company added.

MORE ON IOVANCE BIOTHERAPEUTICS

* Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4810887-iovance-biotherapeutics-inc-iova-q2-2025-earnings-call-transcript]
* Iovance Biotherapeutics Is Waking Up - Price Action Screams Breakout, But Fundamentals Demand Patience [https://seekingalpha.com/article/4804463-iovance-biotherapeutics-is-waking-up-price-action-screams-breakout-but-fundamentals-demand-patience]
* Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug [https://seekingalpha.com/article/4802275-iovance-im-switching-from-sell-to-buy-despite-likely-approval-for-rival-drug]
* Iovance falls after missing Q2 expectation [https://seekingalpha.com/news/4482842-iovance-falls-after-missing-q2-expectation]
* Iovance outlines $250M–$300M 2025 revenue target as restructuring aims to boost margins and expand Amtagvi adoption [https://seekingalpha.com/news/4482264-iovance-outlines-250m-300m-2025-revenue-target-as-restructuring-aims-to-boost-margins-and]